On Friday, May 31, 2019, the FDA convened a public hearing to take comments from more than 100 presenters addressing a wide range of scientific, marketing, safety, and efficacy issues pertaining to products containing cannabis or cannabis-derived compounds. This day-long session was held at the U.S. Food and Drug Administration White Oak Campus in Silver Spring, Maryland.

Read the report here.